<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967157</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-2104</org_study_id>
    <nct_id>NCT04967157</nct_id>
  </id_info>
  <brief_title>Cognitive Effects of Citicoline on Attention in Healthy Men and Women</brief_title>
  <official_title>A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess the Cognitive Effects of a Citicoline Supplement (Cognizin®) on Attention in Healthy Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirin Holdings Company, Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biofortis Clinical Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirin Holdings Company, Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to determine the effects of citicoline on cognitive&#xD;
      performance for attention in healthy Men and Women compared to a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 12-week, randomized, double-blind, placebo-controlled trial of citicoline in&#xD;
      healthy men and women. Cognitive assessments will be performed to determine whether&#xD;
      citicoline administration improves attention, compared to placebo administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite score calculated based on scores from the Computerized Mental Performance Assessment System (COMPASS, Northumbria University, Newcastle upon Tyne, UK) that measure cognitive assessment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standardized scores on the Computerized Mental Performance Assessment System (COMPASS, Northumbria University, Newcastle upon Tyne, UK) that measure cognitive assessment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Dietary Supplement: Placebo supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognizin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Dietary Supplement: Citicoline supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo supplement</intervention_name>
    <description>Cellulose</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citicoline supplement</intervention_name>
    <description>Cognizin®</description>
    <arm_group_label>Cognizin®</arm_group_label>
    <other_name>Cognizin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female, 35-75 years of age&#xD;
&#xD;
          -  Scores ≥24 on the MMSE, ≤15 on the CESD-R, and scores below the population median&#xD;
             (i.e., below 81.25, above 36.8) on the Gradual CPT&#xD;
&#xD;
          -  Self-reported poor attention&#xD;
&#xD;
          -  no health conditions that would prevent him or her from fulfilling the study&#xD;
             requirements on the basis of medical history and routine laboratory test results&#xD;
&#xD;
          -  Understands the study procedures and signs forms providing informed consent to&#xD;
             participate in the study and authorizes the release of relevant protected health&#xD;
             information to the Principal Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  color blindness&#xD;
&#xD;
          -  Known allergy or sensitivity to any of the ingredients in the study products and/or&#xD;
             any ingredients of the breakfast meal provided&#xD;
&#xD;
          -  major medical or neurological illness&#xD;
&#xD;
          -  diagnosis of attention deficit hyperactive disorder (ADHD)&#xD;
&#xD;
          -  female who is pregnant, planning to be pregnant during the study period&#xD;
&#xD;
          -  requiring treatment with a drug which might obscure the action of the study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Kelley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biofortis Clinical Research, Inc. Addison, Illinois, United States, 60101</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Sanoshy</last_name>
    <phone>630-617-2000</phone>
    <email>kristen.sanoshy@mxns.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biofortis Clinical Research, Inc.</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Sanoshy</last_name>
      <phone>630-617-2000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

